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ABSTRACT
Laromustine is a sulfonylhydrazine anticancer prodrug whose cytotoxicity results
from the formation of interstrand cross-links caused by the synergistic action of cogenerated 2-chloroethylating and carbamoylating species. The cytotoxic activities of
Laromustine involve the induction of apoptosis. Described herein is an investigation
into this drug’s effects on apoptotic gene expression in HL-60 cells using qRT-PCR.
Significant changes in the expression levels of 13 genes were observed, most
dramatically in the upregulation of the bcl2-associated athanogene 3 (BAG3) gene.
Given the pro-survival role of BAG3 in the cell, this investigation sought to decrease
BAG3 mRNA levels in HL-60 cells using transient shRNA transfections in conjunction
with qRT-PCR analysis and cell death assays to assess the effect of BAG3 knockdown
on sensitizing cancerous cells to Laromustine-induced cell death.
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INTRODUCTION
Laromustine is a sulfonylhydrazine anticancer prodrug whose main cytotoxic
activity originates from its ability to interfere with DNA replication in dividing cells.1 In
situ, it generates two reactive electrophiles: 90CE and methyl isocyanate (Fig. 1). The
90CE component is understood to be the main contributor to the cytotoxicity of
Laromustine. It inhibits DNA replication in cancerous cells by alkylating DNA at the O6
position of guanine, and this alkylation results in the formation of harmful interstrand
cross-linking of guanine with cytosine.2 Methyl isocyanate is a carbamoylating agent that
can modify sulfhydryl groups, such as cysteine residues in proteins, which can
negatively affect their activity.3 More specifically, methyl isocyanate is thought to inhibit
the proteins O6-alkylguanine-DNA alkyltransferase (AGT) and thioredoxin reductase, as
well as various protein components related to base excision repair, such as DNA
polymerase β and AP endonuclease.3-5 A synergistic effect has been observed for the
90CE and methyl isocyanate components of Laromustine, though the cause of this
synergism has not been definitively established.3
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The damage that Laromustine exerts on a cell’s genetic foundation as well as its
cellular machinery can result in cell death. Although initial studies suggested that
Laromustine induced necrotic death, new investigations have indicated that it activates
apoptotic cell death pathways.6 While many current inquiries involving Laromustine
focus on the drug’s mechanism of inducing cell death, the basis for this particular
investigation stemmed from wanting to more fully characterize the molecular responses
of cancer cells to Laromustine in the context of apoptotic cell death. There are many
pathways involved in apoptosis, each having their own triggers for induction and
execution of cell death.7 Determining what specific apoptotic components are involved
in cell death caused by Laromustine may identify secondary drug targets or targets for
use in clinical pre-screens of cancer patients.
A broad-spectrum investigation regarding the effect of Laromustine on apoptotic
components has been completed as a precursor to this study. A library of 88 primers
corresponding to genes coding for protein components involved in apoptosis was used
in conjunction with quantitative real-time reverse transcriptase PCR (qRT-PCR) analysis
to measure changes in gene expression in HL-60 cells that had been exposed to
Laromustine. Thirteen genes showed significantly altered levels, with the greatest
change seen in levels of the bcl2-associated athanogene 3 (BAG3) gene, which
demonstrated marked upregulation in the presence of Laromustine. Thus, this gene and
its corresponding protein product was selected as a target for further investigation into
the nature of Laromustine’s anticancer activity in a cellular system.
BAG3, also known as CAIR-1 or Bis, is a 74-kDa protein, located in the rough
endoplasmic reticulum, that is a pro-survival component of the Bcl2-associated
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athanogene family, a group of proteins that have been implicated in a variety of
signaling, chaperoning, and cellular death pathways.8,9 Transcription of BAG3 is
regulated by a number of protein factors including Erg1, AibZIP, WT1, and HSF1.10 In
non-neoplastic tissue, BAG3 is only constitutively expressed in skeletal and cardiac
myocytes, but sustained expression levels are significantly increased in a wide variety
of cancerous tissues and cell lines.11,12
In general, the most important role that BAG3 plays in cells relates to promoting
survival and preventing apoptosis. One of the first studies to identify BAG3 used
expression cloning to isolate proteins that bound to the anti-apoptotic protein Bcl-2, and
they subsequently showed that BAG3 interacted strongly with heat shock protein 70
(Hsp70) to regulate and even attenuate apoptosis in cellular systems.13 Other members
of the BAG family, particularly BAG1, have also been identified as chaperones for
Hsp70 due to the BAG domain that is conserved within all members of the family.14
Hsp70’s main purpose in the cell is to regulate the folding of proteins into their native
state; it has also been associated with the export and translocation of proteins as well
as the rehabilitation or degradation of misfolded proteins.15 As a chaperone for Hsp70,
BAG3 is an influential component in regulating processes crucial to proper production of
functional proteins and thus has a large impact on cellular survival. Specifically, BAG3
has been found to promote anti-apoptotic activity in an Hsp70-dependent manner by
inhibiting degradation of polyubiquinated proteins such as Akt and cyclin D1 in cellular
systems.8
In addition to its involvement with Hsp70, BAG3 also is believed to modulate antiapoptotic activity within the cell by interacting with Bcl-2 family proteins. By acting

5

synergistically with Bcl-2, BAG3 has demonstrated the ability to prevent Bax-induced or
Fas-mediated apoptosis.16 BAG3 has also been found to prevent the translocation of
Bax, a pro-apoptotic protein, to the mitochondria in glioblastoma multiforme cells.17
Additionally, the proteins Bcl-XL, Mcl-1, and Bcl-2 are stabilized by BAG3 at the protein
turnover level, promoting cellular survival, and Bcl-XL was shown to form a complex with
BAG3 and Hsp70, further supporting the theory that BAG3 demonstrates anti-apoptotic
activity through protein-protein interactions.18 Lastly, several studies have shown BAG3
involvement in other cellular pathways, such as development, autophagy, and cell
motility and adhesion, but further investigations are needed to more clearly elucidate its
role in these processes.10,12
Because of the crucial role that BAG3 plays in regulating and maintaining cellular
survival, especially in relation to protein management, this member of the BAG family
has also been implicated in a number of cancers. Studies have shown that BAG3 has
significant influence in the development and progression of pancreatic, thyroid, colon,
and prostate cancers as well as neuroblastomas, glioblastomas, lymphomas, and
leukemias.12 In many of these cancer types—specifically pancreatic, thyroid carcinoma,
glioblastoma, and leukemia—higher expression levels of BAG3 in primary tumor
samples have correlated with higher tumor grades, lower patient survival rates, and
higher degrees of drug resistance.17,19-21 This relationship suggests that BAG3 may
serve as a beneficial target for novel cancer treatments as it seems to have an
influential impact within a broad subset of cancers.
The oncogenic capacity of BAG3 appears to be caused by hyperactivity of its
normal functions, which is to sustain survival and prevent induction of cellular death.
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Major advances towards understanding the exact role of BAG3 in contributing to
neoplastic cellular activity have been made in the past few years, and these
investigations have spanned a variety of cancer types. One of the first identifications of
BAG3’s cancerous activity was in osteosarcoma and melanoma systems, where BAG3
was shown to prevent IKK degradation by preventing its association with Hsp70,
thereby prolonging NF-kB activation and promoting cellular survival.22 As mentioned
previously, BAG3 overexpression in glioblastoma has been shown to support prosurvival activity by blocking the translocation of Bax to the mitochondria.17 In a study
involving several thyroid carcinoma cell lines, decreasing BAG3 levels resulted in an
increase of apoptosis triggered by TNF-related apoptosis inducing ligand (TRAIL),
another demonstration of BAG3’s ability to block induction of cellular death in cancerous
systems.21 BAG3 has also been previously shown to associate with the anti-apoptotic
proteins Bcl-XL and Bcl-2 in colon cancer cells, and more recently its association with
these same pro-survival proteins has also been demonstrated in non-small cell lung
cancer.18,23 Additionally, BAG3 has been implicated in processes related to metastasis
through its involvement in cellular motility and adhesion pathways, as well as to
angiogenesis, which was established through demonstrating BAG3’s ability to sustain
ERK1/2 phosphorylation in HUVEC cells.10,11
BAG3 has proven to be a particularly influential player and potential therapeutic
target for leukemias. The trend of BAG3 overexpression and the protein’s role in
preventing apoptosis in leukemic cells was demonstrated clearly by two studies in which
primary cell samples from adult patients with B-cell chronic lymphocytic leukemia (BCLL) and patients with childhood acute lymphoblastic leukemia (ALL) were tested for
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BAG3 expression and then exposed to antisense oligodeoxynucleotides (ODNs) to
decrease levels of BAG3.24 In both cases, treatment with ODNs targeting BAG3
significantly increased the degree of apoptosis in the primary cell samples, even without
drug treatment, and the percentage of cells undergoing apoptosis increased even
further upon addition of chemotherapeutics.25,26 Overexpression of BAG3 has also been
connected to drug resistance in several leukemias, including chronic lymphocytic
leukemia (CLL), chronic myeloid leukemia (CML), and acute myeloid leukemia
(AML).27,28 High expression levels of BAG3 have also been observed in a variety of
leukemic cancer cells lines, including HL-60s, strongly supporting that the model system
mimics the patient phenotype.12
Increased expression of BAG3 in cancerous cell lines has also been observed to
be further induced upon treatment with several anticancer drugs, which include a few
proteasome inhibitors, some nucleoside analogs, and a topoisomerase inhibitor.10,19,29-31
Similarly, we have demonstrated increased BAG3 expression in HL-60 cells upon
exposure to Laromustine. These results indicate that we may have identified alkylating
agents as a new category of anticancer drugs that induce BAG3 upregulation, although
the exact link between BAG3 and Laromustine’s mechanism of action remains unclear.
This overexpression of BAG3 upon exposure to anticancer drugs has been attributed to
a stress response on the part of the cell to compensate for the damage that such drugs
cause.32 In many of these studies demonstrating BAG3 upregulation in response to drug
exposure, knockdown of BAG3 prior to drug treatment has led to increased levels of
cellular death in variety of cell lines.29-31 Hence, we wish to pursue this same line of
inquiry for Laromustine. Given that BAG3 is overexpressed in many cancer types
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(including leukemia and glioblastoma, which Laromustine has shown promising activity
against in various clinical trials) establishing its effect as a tumor promoter may lead to
ways of improving Laromustine’s efficacy as an anticancer drug. Previously, AGT, an
established protein target of Laromustine, has been used as a marker in pre-clinical
screens to determine patient predisposition to the drug. Determining the way in which
BAG3 affects the cytotoxic capacity of Laromustine may lead to a similar outcome and
provide clinicians with a way of selecting patients for Laromustine treatment whose
cancers will be more susceptible to the drug and therefore will respond better to the
treatment.
As a first step in pursuing such a goal, this study investigates whether BAG3
knockdown can sensitize HL-60 cells to the cytotoxic effects of Laromustine. Initially,
small interfering RNA (siRNA) molecules were used to achieve knockdown, but after
optimization attempts, knockdown of BAG3 in HL-60 cells was accomplished using
short hairpin RNA (shRNA), with degree of attained knockdown assessed using qRTPCR analysis. Although a trend of BAG3 knockdown was demonstrated, further studies
need to be completed in order to maximize the BAG3 shRNA knockdown potential.
Following this, cell death assays measuring cytotoxicity or cell proliferation will be used
to determine the effect that BAG3 knockdown has on sensitizing cancer cells to
Laromustine-induce cell death.

MATERIALS & METHODS
Cell Culture
HL-60 cells were obtained from American Type Culture Collection (Rockville,
MD) and grown in RPMI 1640 media (Lonza, Basel, Switzerland) supplemented with
9

0.1% gentamycin and 10% fetal bovine serum (Fisher Scientific, Hampton, NH).
Cultures were maintained between 3 x 105 and 7 x 105 cell/mL at 37°C and 5% CO2.
Cell viability was determined using trypan blue exclusion, and cell count was completed
using a Cellometer (Nexcelom Biosciences, Lawrence, MA).
Small interfering RNA and short hairpin RNA
Four BAG3 siRNA constructs were purchased as part of the Qiagen (Hilden,
Germany) FlexiTube Gene Solution package. As a control to asses transfection
efficiency, MAPK1 siRNA was also purchased from Qiagen. All siRNA samples were
diluted with sterile, RNase-free water to appropriate concentrations for transfection.
Bacterial glycerol stock containing pLKO.1-puro vectors with a BAG3 shRNA
clone was ordered from Sigma-Aldrich (St. Louis, MO). Culturing of the clonal cell line
for plasmid purification was completed using the manufacturer’s recommended
procedure. Briefly, ice splinters from the glycerol stock were transferred to a sterile
culture tube containing 0.5 mL of LB without antibiotics and incubated for 30 min at
37°C. A sterile glass rod was used to streak the culture onto an LB agar plate containing
ampicillin, and plates were incubated at 37°C for 18 hr. Several colonies were then
isolated and used to inoculate cultures for plasmid purification, which was completed
using the QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany) and accompanying
protocol.
Transient & Stable Transfections
Purchased BAG3 siRNA or purified BAG3 shRNA was used to transiently
transfect HL-60 or HeLa cells via electroporation according to established protocols for
an Amaxa Nucleofector II device (Amaxa Biosystems). The protocols for each cell type
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are described briefly as follows. A 100 uL volume of transfection buffer from the
Nucleofector Kit V (Lonza, Basel, Switerzland) was used to transfect 2 x 106 HL-60 cells
with 30 pmol of siRNA or 2 ug of shRNA plasmid. A 100 uL volume of transfection buffer
from the Nucleofector Kit R was used to transfect 1 x 106 HeLa cells with 30 pmol of
siRNA. Equivalent volumes of RNase-free water or elution buffer were added to
negative control samples for the transfection.
To establish a stable transfection of BAG3 shRNA in HL-60 cells, 1 x 106 cells
were transfected with 2 ug of purified shRNA plasmid as described above. Posttransfection, cells were incubated under the previously listed conditions in T-25 culture
flasks for 24 hr, after which stable transfectants were established using puromycin
selection at 2 ug/mL for 3 days (Enzo Life Sciences, Farmingdale, NY). A culture of
mock-transfected HL-60s was also established, in the absence of puromycin, to serve
as a negative control for BAG3 knockdown.
Drug Treatment
For transiently transfected samples, cell culture samples were incubated at the
previously listed conditions in 15 mL falcon tubes for 16 hr before Laromustine was
added at a final concentration of 100 µM. For stably transfected samples, the
appropriate number of cells was extracted from cultures before exposure to
Laromustine. Equivalent volumes of DMSO were added as a negative control for drug
treatment. Treated cell samples were incubated under the previously stated conditions
with drug or DMSO for 6 hr before total RNA was collected.
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RNA Isolation & qRT-PCR
Total RNA was extracted as outlined in the RNeasy Plus Mini Kit (Qiagen,
Hilden, Germany) protocol. After quantification by optical density using a NanoDrop
1000 (Thermo Scientific, Waltham, MA), all RNA samples were diluted using RNasefree water to a concentration of 28 ng/µL. All qRT-PCR assays were carried out using
the QuantiFast SYBR Green RT-PCR Kit (Qiagen) on an Applied Biosystems StepOne
Real-Time PCR System (Life Technologies, Carlsbad, CA). The library of 88 apoptosis
gene primers, 8 housekeeping gene primers, and BAG3 primer were obtained from
Real Time Primers (Elkins Park, PA). Analysis of gene expression data was calculated
using the comparative ΔCT method to generate ΔΔCT and fold change values as a way
to quantify the relative amount of mRNA.

RESULTS & DISCUSSION
Previous and current investigations examining the cytotoxic nature of
Laromustine have indicated that the damage induced by this anticancer drug triggers
the induction of apoptosis, a form of programmed cell death. In order to examine, on a
broad scale, the molecular response of cancer cells to Laromustine, a primer library of
88 genes associated with apoptosis was chosen as a means to analyze the effect that
the drug has on apoptotic proteins. Through screening this library, the hope was to
identify genes whose role in Laromustine-induced apoptosis could be investigated to
contribute to our understanding of how Laromustine exerts its cytotoxic activity.
Laromustine upregulates BAG3 mRNA in HL-60 cells
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A library of primers corresponding to 88 genes associated with apoptosis was
used in conjunction with qRT-PCR analyses to determine changes in gene expression
levels in HL-60 cells treated with Laromustine at 100 µM for 6 hours. Several screens of
the entire library were performed, and 13 targets were ultimately identified as having
significant changes in gene expression upon drug exposure (Fig. 2 and Table 1). Genes
were determined as having significantly altered expression if a gene’s individual ∆∆CT
value exceeded the threshold of ±2 standard deviation from the mean ∆∆CT value for all
88 genes. Within this group, the majority of genes demonstrated less than or equal to a
ten-fold change in expression due to drug exposure; however, the BAG3 gene had
almost a 200-fold upregulation in the presence of Laromustine, which is a highly
significant change in expression level (Fig. 2). Hence, due to this marked increase,
BAG3 was chosen as a promising target for future investigations.
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siRNA knockdown of BAG3 in HL-60 cells
Previous studies investigating the role BAG3 in various types of cancer have
demonstrated a pattern of BAG3 upregulation upon exposure to certain anticancer
drugs, and they also have shown that the subsequent knockdown of BAG3 resulted in
increased sensitivity to drug-induced cell death.29-31 The goal of this investigation was to
achieve the same outcome with the anticancer drug Laromustine. Initially, transient
transfection of Laromustine-treated HL-60s with small interfering RNA (siRNA) was
chosen to achieve knockdown of BAG3. Knockdown by siRNA is a common RNAi
technique used to decrease mRNA levels of a target gene in mammalian cells;
however, no experimentally validated siRNA sequence existed for BAG3 at the time of
this investigation. Hence, we chose to purchase a set of four different siRNAs predicted
by the vendor (Qiagen) to target BAG3 mRNA in human cell lines so as to maximize the
potential for a successful knockdown.
Prior to using these sequences, however, we attempted to validate the
transfection technique—in which an Amaxa Nucleofector device was used to
electroporate cells—by assessing siRNA knockdown of a validated target MAPK1.
Although optimization ventures were attempted, we were not able to demonstrate
significant MAPK1 knockdown using a validated siRNA sequence, as qRT-PCR
analysis revealed almost no change between cells transfected with siRNA and cells
transfected with a vehicle control. As prior experiments had shown efficient transfection
with a control GFP-containing plasmid provided by the Nucleofector vendor (Lonza), the
inefficient knockdown was assumed to be due to complications with the knockdown and
not the transfection technique. In a final effort to test the effectiveness of siRNA
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knockdowns, one of the BAG3 siRNAs was chosen to be transfected into HL-60s that
would be subsequently treated with Laromustine, with the idea that effect of the siRNAs
may be more detectable against a highly upregulated gene such as BAG3. While some
effect was observed, it was not significant enough to demonstrate that the siRNAs were
performing to their full efficiency.
shRNA knockdown of BAG3 in HL-60 cells
Since attempts at knockdown of BAG3 with siRNA produced inconclusive results
and transfection of HL-60s was successful using the GFP-containing control plasmid,
we decided to change the RNAi technique to knockdown of BAG3 via small hairpin RNA
(shRNA). While there were several factors that influenced this choice, the experimental
validation of the shRNA sequence we ultimately purchased was the main reason for our
confidence in choosing this new approach. Initially, investigations into knockdown of
upregulated BAG3 in HL-60s due to Laromustine exposure using shRNA followed the
same protocol of transient transfection via electroporation. Preliminary results using
shRNA to achieve BAG3 knockdown in this manner demonstrated an approximately
40% decrease in mRNA levels. While this is a promising trend, a more significant
degree of knockdown is ultimately desired.
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Given that the shRNA plasmid purchased contained a resistance gene for
selection in mammalian cells, we elected to attempt establishing a culture of HL-60s
with stable expression of the BAG3 shRNA. To do so, three groups of HL-60s were
transfected—one with BAG3 shRNA plasmid, two with equivalent volumes of the vehicle
reagent—according to the previously used electroporation protocol and incubated
overnight in normal growth media. At 24 hours post-transfection, the shRNA-transfected
culture and one of the mock-transfected cultures were switched to media containing
puromycin (4 ug/mL), with the other mock-transfected culture maintained in normal
growth media. Cells were monitored until stable cultures were established, with cell
count and viability data taken every 24 hours after start of the selection period. After 4
days of monitoring, the shRNA-transfected cells and mock-transfected cells maintained
in the selection media showed almost no viable cells, indicating that establishing a
culture that stably expressed the BAG3 shRNA plasmid had not been successful.
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FUTURE WORK
While further optimizations of transient transfection of HL-60 cells with BAG3
shRNA will be pursued in an effort to complete this study, the focus of the investigation
will shift towards establishing cell cultures that stably expresses the BAG3 shRNA
plasmid. In doing so, the consistency and degree BAG3 knockdown should be
maximized, and the process of investigating the effect of BAG3 knockdown will be
streamlined. Additional attempts at establishing stable expression in HL-60s will be
completed, using a lower puromycin concentration to decrease the selection stringency,
as it may have been too high previously to allow for the resistance gene in the shRNA
plasmid to compensate. Also, we will turn to an alternative transfection technique,
lipofection, in an attempt to establish stable BAG3 shRNA expression in HL-60 cells as
well as U138 cells, a glioblastoma cell line also used in Laromustine-related
investigations.
Once stable shRNA expression in either, or both, of these cell lines results in a
highly significant degree of BAG3 knockdown, cell death assays will be used to
determine the effect of decreasing BAG3 mRNA levels on sensitizing cancer cells to
Laromustine. Two assays (the ViaLight bioassay and the Click-iT EdU assay) have
been chosen as appropriate methods for doing so. The ViaLight assay measures
luminescence of cellular ATP to determine cell viability, hence providing cytotoxicity
data. The Click-iT EdU assay uses a modified nucleoside in combination with click
chemistry—in which an alkyne group on a synthetic, supplemental nucleoside reacts
with an azide group on a fluorophore—to detect new DNA, thereby providing
information on the degree of cell proliferation. Using both a cell death assay and a cell

18

proliferation assay to examine the effects of BAG3 knockdown will produce a
comprehensive examination of the degree to which cancer cells are sensitized to
Laromustine. If BAG3 knockdown does significantly increase the cytotoxic effects of
Laromustine, this finding may have implications both in the lab and in the clinic as it
establishes a way to improve the drug’s efficacy, which would be a promising
advancement in the war on cancer.
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